loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Pirtobrutinib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Pirtobrutinib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PATENTS

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: Loxo-305, 2101700-15-4, Pirtobrutinib [usan], Jna39i7zvb, (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide, Ly3527727
    Molecular Formula
    C22H21F4N5O3
    Molecular Weight
    479.4  g/mol
    InChI Key
    FWZAWAUZXYCBKZ-NSHDSACASA-N
    FDA UNII
    JNA39I7ZVB
    Pirtobrutinib is an orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
    2.1.2 InChI
    InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1
    2.1.3 InChI Key
    FWZAWAUZXYCBKZ-NSHDSACASA-N
    2.1.4 Canonical SMILES
    CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N
    2.1.5 Isomeric SMILES
    C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N
    2.2 Other Identifiers
    2.2.1 UNII
    JNA39I7ZVB
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)pyrazole-4-carboxamide

    2. Loxo-305

    2.3.2 Depositor-Supplied Synonyms

    1. Loxo-305

    2. 2101700-15-4

    3. Pirtobrutinib [usan]

    4. Jna39i7zvb

    5. (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide

    6. Ly3527727

    7. Rxc-005

    8. Ly-3527727

    9. 1h-pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1s)-2,2,2-trifluoro-1-methylethyl)-

    10. 1h-pyrazole-4-carboxamide, 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(1s)-2,2,2-trifluoro-1-methylethyl]-

    11. Btk Inhibitor 16

    12. Unii-jna39i7zvb

    13. Pirtobrutinib [inn]

    14. Pirtobrutinib [jan]

    15. Loxo305

    16. Pirtobrutinib (loxo-305)

    17. Pirtobrutinib [who-dd]

    18. Chembl4650485

    19. Schembl19014257

    20. Gtpl11628

    21. Glxc-25733

    22. Ex-a5016

    23. Who 11681

    24. Bl180882

    25. Hy-131328

    26. Cs-0133286

    27. Loxo-305;ly 3527727; Rxc-005

    28. 5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide

    29. 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide

    2.4 Create Date
    2017-08-04
    3 Chemical and Physical Properties
    Molecular Weight 479.4 g/mol
    Molecular Formula C22H21F4N5O3
    XLogP33.3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count7
    Exact Mass479.15805220 g/mol
    Monoisotopic Mass479.15805220 g/mol
    Topological Polar Surface Area125 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity719
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    Post Enquiry
    POST ENQUIRY